✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹2,847 Cr.
P/E
281.88

Key Ratios

Market cap
Market cap
2,847 Cr
PE
PE
281
Prom Holding
Prom Holding
68.85 %
ROE (%)
ROE (%)
7.19
ROCE (%)
ROCE (%)
11.08
Div Yield (%)
Div Yield (%)
0.61
Sales
Sales
1,699 Cr
OPM (%)
OPM (%)
13.41 %
Debt to Equity
Debt to Equity
0.60

About

Hikal Limited offers solutions across the life sciences value chain. The company is engaged in… Read more
Low
225
52W Range
High
465
  • Hikal
  • Suven Life Sciences
  • Cohance Lifesciences
  • TJI Pharma - API & CRAMS

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

9 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

40 %
(as of Mar 19)
Gabapentin - Market Share

Revenue mix

Product Wise Break-Up

Product Wise Break-Up - Crop Protection

Product Wise Break-Up - Pharmaceuticals

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

    Select a Metric
    • Total reactor capacity (kL)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Balaji Amines Ltd.

    FAQs on Hikal Ltd. Business

    Hikal Limited provides a wide range of solutions in the life sciences value chain including manufacturing chemical intermediates, specialty chemicals, active pharma ingredients, and contract research services to global clients.

    Hikal major competitors are Suven Life Sciences, Cohance Lifesciences, Piramal Pharma, Dishman Carbogen Amc, Sun Pharma Adv. Res, Zenotech Laboratorie, Jeevan Scientific.
    Market Cap of Hikal is ₹2,847 Crs.
    While the median market cap of its peers are ₹4,239 Crs.

    Hikal seems to be less financially stable compared to its competitors.
    Altman Z score of Hikal is 2.7 and is ranked 6 out of its 8 competitors.

    Company Filing

    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release May Aug Nov Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation May Aug Sep Nov Mar Jun Sep Dec Mar Jun Sep Dec Feb Mar May Jun Aug Sep Dec Mar Jun Sep Dec Jun Mar Jun Mar Jun Sep Dec Mar Sep Dec Mar Jun Dec Jun Sep Dec Sep Dec
    Conference Call Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Mar Sep Mar Sep Mar Sep
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material